Cite
HARVARD Citation
Xu, Z. et al. (2022). A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjects. Expert opinion on investigational drugs. pp. 737-746. [Online].